ArticleScientific reports2026
Effect of statins and ACE inhibitors on the metabolome in the Adolescent Type 1 Diabetes cardio-renal Intervention Trial (AdDIT) cohort.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01581476. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomised, Double Blind, Placebo Controlled Trial of Angiotensin Converting Enzyme Inhibitors and Statins in the Prevention of Long Term Complications in Young People With Type 1 Diabetes
Open the trial in the graphWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Adolescence represents a pivotal period for the development of early diabetes-related vascular complications, primarily driven by chronic hyperglycemia and associated metabolic disturbances. Metabolomics provides a promising tool to identify biomarkers reflecting these early changes. The present study compared metabolomic profiles between adolescents with and without type 1 diabetes and assessed the impact of glycemia and short-term treatment with statins and/or ACE inhibitors on metabolite trajectories. Metabolomic data were obtained via the Nightingale platform from 341 adolescents with type 1 diabetes from the AdDIT study and 81 age- and sex-matched peers without diabetes. Two hundred and forty-nine metabolites, with 45 prioritized due to well-established links with cardiovascular disease- including lipid subfractions, amino acids, ketone bodies, and markers of renal function and inflammation-were measured at a mean age of 14.0 ± 1.8 years and re-assessed after 3.5 years in those with diabetes. At baseline, significant differences were observed in glucose, ketone bodies, amino acids, and lipid classes. Over time, adolescents with diabetes showed increases in lipid subfractions, acetoacetate, and GlycA, with HbA1c positively associated with atherogenic lipidome components. Findings from the trial arm provided strong evidence that statins attenuated rises in LDL-cholesterol (1.90 [1.79, 2.01] vs. 2.38 [2.28, 2.49] mmol/l), and weaker evidence suggestive of a small effect of ACE inhibitors in preserving HDL-cholesterol (1.50 [1.45, 1.54] vs. 1.39 [1.34, 1.43] mmol/l). These findings suggest widespread glycemia-related metabolomic perturbations in adolescents with type 1 diabetes, partially mitigated by statins and ACE inhibitors, supporting their cardioprotective role.Clinical registration: ClinicalTrials.gov ID NCT01581476 (13/04/2012) https://clinicaltrials.gov/study/NCT01581476 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.